Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PFKFB4 | Q16877 | 6/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 6/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947561 | 0.87 | NPSR1 (0.35) | HTR6PFKFB4PFKFB3NPSR1L3MBTL1 | |
| SCHEMBL3947273 | 0.77 | HTR6 (0.40) | HTR6NPSR1L3MBTL1PTGER4CA1 | |
| SCHEMBL806073 | 0.77 | PFKFB4 (0.56) | PFKFB4PFKFB3 | |
| SCHEMBL788454 | 0.76 | PFKFB4 (0.55) | PFKFB4PFKFB3 | |
| SCHEMBL2226181 | 0.74 | NPSR1 (0.60) | PFKFB4PFKFB3NPSR1L3MBTL1CMA1 | |
| Hydrochloric Acid SCHEMBL6712744 | 0.73 | NPSR1 (0.59) | PFKFB4PFKFB3NPSR1L3MBTL1CMA1 | |
| SCHEMBL7483221 | 0.72 | NPSR1 (0.36) | HTR6PFKFB4PFKFB3NPSR1L3MBTL1 | |
| SCHEMBL4658351 | 0.71 | NPSR1 (0.47) | HTR6PFKFB4PFKFB3NPSR1L3MBTL1 | |
| SCHEMBL7473168 | 0.69 | HTR6 (0.41) | HTR6PTGER4CA1CA2 | |
| SCHEMBL3681719 | 0.69 | NPSR1 (0.36) | HTR6PFKFB4PFKFB3NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | HTR6 1402/4885PFKFB4 2318/4885PFKFB3 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.